{"id":1411,"date":"2009-04-20T16:54:58","date_gmt":"2009-04-20T16:54:58","guid":{"rendered":"http:\/\/localhost.localdomain\/wpmu\/htb\/?p=1411"},"modified":"2013-08-16T14:30:41","modified_gmt":"2013-08-16T14:30:41","slug":"effect-of-tenofovir-on-abacavir-phosphorylation","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/1411","title":{"rendered":"Effect of tenofovir on abacavir phosphorylation"},"content":{"rendered":"<p><strong>hiv-druginteractions.org<\/strong><\/p>\n<p><strong>Intracellular concentrations of the active phosphorylated metabolites of abavavir (carbovir triphosphate) and tenofovir (tenofovir disphosphate) were determined in HIV-positive, treatment-naive subjects following administration of abacavir (600 mg once daily) and tenofovir (300 mg once daily) alone and in combination.<\/strong><\/p>\n<p>The addition of tenofovir had no effect on carbovir triphosphate AUC (1694 vs 1895 fmol.h\/106 cells, alone vs combination), but there was a trend towards an increase in tenofovir diphosphate AUC on addition of abacavir, though this was not statistically significant (1209 vs 2700 fmol.h\/106cells, alone vs combination, p=0.08).<\/p>\n<p>Interestingly, viral decay during tenofovir plus abacavir dual therapy was 0.04 log10\/day faster than during tenofovir monotherapy.<\/p>\n<h3>Comment<\/h3>\n<p><strong>This interesting study still doesn\u0092t help shed light on why triple-nuke combinations including abacavir and tenofovir disastrously underperformed clinically.<\/strong><\/p>\n<p>Reference:<\/p>\n<p>Goicoechea M et al. Viral dynamics and pharmacokinetics in vivo of tenofovir disoproxil fumarate and abacavir: evidence of a non-additive antiviral effect. 16th CROI, Montreal, 2009. Abstract 703. <a href=\"http:\/\/www.retroconference.org\/2009\/Abstracts\/33853.htm\"><br \/>\nhttp:\/\/www.retroconference.org\/2009\/Abstracts\/33853.htm<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>hiv-druginteractions.org Intracellular concentrations of the active phosphorylated metabolites of abavavir (carbovir triphosphate) and tenofovir (tenofovir disphosphate) were determined in HIV-positive, treatment-naive subjects following administration of abacavir (600 mg once daily) and tenofovir (300 mg once daily) alone and in combination. &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,34],"tags":[63],"class_list":["post-1411","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-pk-and-drug-interactions","tag-croi-2009"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/1411","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=1411"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/1411\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=1411"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=1411"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=1411"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}